<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Reported-in-House" bill-type="olc" dms-id="HCD1AAE88552847C598669A13874CB6E5" key="H" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 2557 RH: Prostate Cancer Misdiagnosis Elimination Act of 2017</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-12-06</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">IB</distribution-code>
		<calendar display="yes">Union Calendar No. 331</calendar>
		<congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session>
		<legis-num display="yes">H. R. 2557</legis-num>
		<associated-doc display="yes" role="report">[Report No. 115–449, Part I]</associated-doc>
		<current-chamber display="yes">IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action display="yes">
			<action-date date="20170519">May 19, 2017</action-date>
			<action-desc><sponsor name-id="B001275">Mr. Bucshon</sponsor> (for himself, <cosponsor name-id="P000604">Mr. Payne</cosponsor>, <cosponsor name-id="C001072">Mr. Carson of Indiana</cosponsor>, <cosponsor name-id="M001190">Mr. Mullin</cosponsor>, and <cosponsor name-id="R000515">Mr. Rush</cosponsor>) introduced the following bill; which was referred to the <committee-name added-display-style="italic" committee-id="HIF00" deleted-display-style="strikethrough">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc>
		</action>
		<action>
			<action-date date="20171206">December 6, 2017</action-date>
			<action-desc>Additional sponsors: <cosponsor name-id="W000813">Mrs. Walorski</cosponsor> and <cosponsor name-id="B001284">Mrs. Brooks of Indiana</cosponsor></action-desc>
		</action>
		<action>
			<action-date date="20171206">December 6, 2017</action-date>
			<action-desc>Reported from the <committee-name added-display-style="italic" committee-id="HIF00" deleted-display-style="strikethrough">Committee on Energy and Commerce</committee-name> with an amendment</action-desc>
			<action-instruction>Strike out all after the enacting clause and insert the part printed in italic</action-instruction>
		</action>
		<action><action-date>December 6, 2017</action-date><action-desc>The <committee-name committee-id="HWM00">Committee on Ways and Means</committee-name> discharged; committed to the Committee of the Whole House on the State of the Union and ordered to
			 be printed</action-desc><action-instruction>For text of introduced bill, see copy of bill as introduced on May 19, 2017</action-instruction></action><action display="yes">
			<action-desc display="yes"><pagebreak></pagebreak></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title display="yes">To amend title XVIII of the Social Security Act to provide for coverage under the Medicare program
			 of certain DNA Specimen Provenance Assay clinical diagnostic laboratory
			 tests.<pagebreak></pagebreak></official-title>
	</form>
	<legis-body changed="added" committee-id="HIF00" display-enacting-clause="yes-display-enacting-clause" id="H55523B399A57478DA439C955965EDE18" reported-display-style="italic" style="OLC">
 <section id="H75A9C36E0AE44D698A3906326320E952" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Prostate Cancer Misdiagnosis Elimination Act of 2017</short-title></quote>.</text> </section><section id="H37A34582560248D999D4FDF5C85F4D39"><enum>2.</enum><header>Coverage of certain DNA Specimen Provenance Assay clinical diagnostic laboratory tests under Medicare</header> <subsection id="HC2923F06DB98495592976BBB8D5B7135"><enum>(a)</enum><header>Coverage</header><text display-inline="yes-display-inline">Section 1862(a)(1) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395y">42 U.S.C. 1395y(a)(1)</external-xref>) is amended—</text>
 <paragraph id="H464C836675F940EB80F20D03BB9CC1E6"><enum>(1)</enum><text>in subparagraph (O), by striking <quote>and</quote> at the end;</text> </paragraph><paragraph id="H3D8FFE797C5344E69428ED9F9F3EFCC4"><enum>(2)</enum><text>in subparagraph (P), by striking the semicolon at the end and inserting <quote>, and</quote>; and</text>
 </paragraph><paragraph id="H9C421C019EDD4ADB99415332B9170AC4"><enum>(3)</enum><text>by adding at the end the following new subparagraph:</text> <quoted-block changed="added" committee-id="HIF00" display-inline="no-display-inline" id="HEA7D3F64764E42AC9F246F536EF75FFF" reported-display-style="italic" style="OLC"> <subparagraph id="HBEE042133FCA4711B01161FCE8917827" indent="up1"><enum>(Q)</enum><text display-inline="yes-display-inline">in the case of a DNA Specimen Provenance Assay clinical diagnostic laboratory test (DSPA test) furnished on or after the date specified in section 1834A(j)(4), unless the DSPA test is furnished to an individual enrolled under part B who has had a prostate cancer biopsy the results of which are positive, the DSPA test is furnished with respect to such biopsy, and the DSPA test is ordered by the physician who furnished the prostate cancer biopsy that obtained the specimen tested;</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection id="HA0E719ECF2464AF6AD1D398F92400F9A"><enum>(b)</enum><header>Temporary payment amount for certain tests furnished before 2028 and related requirements</header><text>Section 1834A of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395m-1">42 U.S.C. 1395m–1</external-xref>) is amended—</text> <paragraph id="H24D373AC9DDE4A1AAB0B3A3130A8259D"><enum>(1)</enum><text>in subsection (b)(1)(A), by striking <quote>and (d)</quote> and inserting <quote>, (d), and (j)</quote>; and</text>
 </paragraph><paragraph id="HBE394B823F7C4D6C9F3A6E74D5DB2398"><enum>(2)</enum><text>by adding at the end the following new subsection:</text> <quoted-block changed="added" committee-id="HIF00" display-inline="no-display-inline" id="HDF354C0FC29F4956837B3A8114DAEF07" reported-display-style="italic" style="OLC"> <subsection id="H7888D97B04D74F0896B86789725D38AD"><enum>(j)</enum><header>DNA Specimen Provenance Assay clinical diagnostic laboratory tests</header> <paragraph id="H1F51AE2C0017401882CE81D307707505"><enum>(1)</enum><header>Temporary payment amount for certain tests furnished before 2028</header><text>With respect to a DNA Specimen Provenance Assay clinical diagnostic laboratory test furnished on or after the date specified in paragraph (4) and before January 1, 2028, the payment amount under this section for such test shall be equal to $200.</text>
							</paragraph><paragraph id="H16780F9D31C14717A03008FA283B1588"><enum>(2)</enum><header>HCPCS code and modifier assignment</header>
 <subparagraph id="H54CF71CC5D874CEAAE6EC99C624E1B98"><enum>(A)</enum><header>In general</header><text>The Secretary shall assign one or more HCPCS codes to the DNA Specimen Provenance Assay clinical diagnostic laboratory test and may use a modifier to facilitate making payment under this section with respect to such test.</text>
 </subparagraph><subparagraph id="H4AAC77F9F0504937819428495F7B35E4"><enum>(B)</enum><header>Identification of DNA match on claim</header><text>The Secretary shall require an indication on a claim for a DNA Specimen Provenance Assay clinical diagnostic laboratory test of whether the DNA of the prostate biopsy specimen for such test matches the DNA of the individual with respect to whom the test was ordered. Such indication may be made through use of a HCPCS code, a modifier, or other means, as determined appropriate by the Secretary.</text>
								</subparagraph></paragraph><paragraph id="H3AB59CE4EF5C4550A1FC1E76F8782933"><enum>(3)</enum><header>DNA match review</header>
 <subparagraph commented="no" id="HBBDAA442E7A14EDBBE3AF79507A734E2"><enum>(A)</enum><header>In general</header><text>The Secretary shall review at least three years of claims under part B for DNA Specimen Provenance Assay clinical diagnostic laboratory tests to identify whether the DNA of the prostate biopsy specimens for such tests matched the DNA of the individuals with respect to whom such tests were ordered.</text>
 </subparagraph><subparagraph commented="no" id="H8ACFB6793B3B47D1B839CB65F189D21E"><enum>(B)</enum><header>Posting on Internet website</header><text>Not later than July 1, 2024, the Secretary shall post on the Internet website of the Centers for Medicare &amp; Medicaid Services the findings of the review conducted under subparagraph (A).</text>
 </subparagraph></paragraph><paragraph id="HC9C376C8509A4159A6E69683B3861D5E"><enum>(4)</enum><header>Date specified</header><text display-inline="yes-display-inline">For purposes of paragraph (1) and section 1862(a)(1)(Q), the date specified in this paragraph is the first day of the second calendar quarter that begins at least 180 days after the date of the enactment of this subsection.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
				</paragraph></subsection></section></legis-body>
	<endorsement display="yes">
		<action-date date="20171206">December 6, 2017</action-date>
		<action-desc>Reported from the <committee-name added-display-style="italic" committee-id="HIF00" deleted-display-style="strikethrough">Committee on Energy and Commerce</committee-name> with an amendment</action-desc><action-date>December 6, 2017</action-date><action-desc>The <committee-name committee-id="HWM00">Committee on Ways and Means</committee-name> discharged; committed to the Committee of the Whole House on the State of the Union and ordered to
			 be printed</action-desc></endorsement>
</bill>


